Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vismodegib (GDC-0449) 是一种刺猬抑制剂,IC50值为 3 nM。它还可抑制 P-gp 和ABCG2的活性,IC50值分别为 3.0 μM 和 1.4 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 575 | 现货 | ||
10 mg | ¥ 897 | 现货 | ||
50 mg | ¥ 2,260 | 现货 | ||
100 mg | ¥ 3,331 | 现货 | ||
200 mg | ¥ 4,195 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 575 | 现货 |
产品描述 | Vismodegib (GDC-0449) is a hedgehog pathway inhibitor (IC50: 3 nM). It also inhibits P-gp (IC50: 3.0 μM), ABCG2 (IC50: 1.4 μM). |
靶点活性 | Hedgehog:3 nM (cell free), P-gp:3.0 μM, ABCG2:1.4 μM |
体外活性 | Vismodegib (GDC-0449) is a potent inhibitor of two ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, Vismodegib increased retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitized these cells to mitoxantrone, an antineoplastic ABCG2 substrate. Vismodegib also resensitized human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC(50) values of Vismodegib for inhibition of ABCG2 and Pgp were approximately 1.4 and approximately 3.0 μM, respectively [2]. GDC-0449 inhibited cell growth in cisplatin-na?ve and -resistant cells. In both cell types, GDC-0449 increased [Ca(2+)](cyto) and reduced endoplasmatic [Ca(2+)](ER) [3]. |
体内活性 | Oral dosing of vismodegib caused tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent CRC models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that vismodegib inhibits Gli1 with a similar IC(50) in both the medulloblastoma and D5123 models (0.165 μmol/L ±11.5% and 0.267 μmol/L ±4.83%, respectively). Pathway modulation was linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of vismodegib is associated with >80% repression of the Hh pathway [4]. |
细胞实验 | MDCKII cells were plated into 24-well plates at a density of 3 x 10^5 cells per well and were allowed to attach. The medium was then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM Vismodegib) in DMSO or DMSO alone as control, and nonfluorescent calcein-AM was added to a final concentration of 1.0 μM and incubated at 37°C for 2 hours. Cells were then washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4°C. The lysate was then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein was quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Reader using an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations were performed in the dark. All readings are expressed as mean ± SEM normalized to the control [2]. |
动物实验 | Female CD-1 nude mice (weighing 25–28 g) were administered oral doses of 5, 15, 50, and 100 mg/kg (free base equivalent) of vismodegib hydrochloride salt in 0.5% methylcellulose/0.2% Tween 80 (MCT). Blood samples (~1 mL) were collected up to 24 hours postdose via cardiac puncture (terminal collection) into tubes containing potassium ethylenediaminetetraacetic acid (K2EDTA) anticoagulant. Immediately on the collection, the blood was mixed with K2EDTA and stored on ice. Within 30 minutes, blood samples were centrifuged at approximately 1000 to 1500 × g for 5 minutes at 4°C, and plasma was harvested. The plasma samples were stored at ?80°C until analysis. Concentrations of vismodegib were determined by LC/MS/MS as described previously [4]. |
别名 | Erivedge, GDC-0449, RG 3616, 维莫德吉 |
化合物与蛋白结合的复合物 |
Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28 |
分子量 | 421.3 |
分子式 | C19H14Cl2N2O3S |
CAS No. | 879085-55-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 78 mg/mL (185.1 mM)
Ethanol: Insoluble
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3736 mL | 11.868 mL | 23.7361 mL | 59.3401 mL |
5 mM | 0.4747 mL | 2.3736 mL | 4.7472 mL | 11.868 mL | |
10 mM | 0.2374 mL | 1.1868 mL | 2.3736 mL | 5.934 mL | |
20 mM | 0.1187 mL | 0.5934 mL | 1.1868 mL | 2.967 mL | |
50 mM | 0.0475 mL | 0.2374 mL | 0.4747 mL | 1.1868 mL | |
100 mM | 0.0237 mL | 0.1187 mL | 0.2374 mL | 0.5934 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vismodegib 879085-55-9 Autophagy GPCR/G Protein Membrane transporter/Ion channel Stem Cells Hedgehog/Smoothened ABC GDC0449 Hedgehog Inhibitor RG3616 inhibit Erivedge RG-3616 GDC-0449 RG 3616 GDC 0449 维莫德吉 inhibitor